Lion TCR
Singapore’s Lion TCR secures $40M in Series B2 financing led by Chinese investors
Lion TCR, a Singapore-based clinical-stage T-cell immunotherapy company, has announced the successful completion of its $40 million Series B2 financing round. Guangzhou…
